Dosing & Uses
Chemotherapy-Induced Neutropenia
Pending FDA approval for using in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN)
Next:
Pharmacology
Mechanism of Action
First-in-class selective immunomodulating microtubule-binding agent (SIMBA)
Binds to colchicine-binding site of tubulin, which releases the immune defense protein, GEF-H1, that activates a signaling transduction pathway, leading to dendritic cell maturation and its innate and adaptive immune activity
Has the potential to directly kill cancer cells; also has the potential to increase maturation of dendritic cells, resulting in increased antigen presentation and T-cell activation, which potentially contributes to its anticancer effects
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
